PAUL HARTMANN AG has acquired Whitestone Acquisition Corp.
The private shareholders of Whitestone Acquisition Corp. have sold the company to PAUL HARTMANN AG (HARTMANN). Financial details have not been disclosed.
HARTMANN, headquartered in Heidenheim, Germany, is a worldwide leader in wound management, incontinence management and risk prevention products in the operating room. Together with the existing US subsidiary, HARTMANN-Conco, Inc. in Rock Hill, South Carolina, HARTMANN consolidates its position in the nursing home and home care sector, the most important market for incontinence products. With this acquisition, the USA will become the third largest market for HARTMANN after Germany and France. The company also sees great opportunities for the establishment of system solutions for inpatient and outpatient care.
Whitestone Acquisition Corp., based in Bloomington, Indiana, is a manufacturer of high-quality adult disposable incontinence products such as briefs, liners and underpads. Formed in 1995, Whitestone annually produces and distributes products for over US$40 million. The corporation primarily serves the institutional long-term care and healthcare markets, markets which are growing 7% a year due to demographic trends.
Oaklins' team in Germany advised HARTMANN on the acquisition of Whitestone Acquisition Corp.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more